MedTrace Logo

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

NCT02291887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2017-11-17

No results posted yet for this study

Summary

A cohort of patients responsive to treatment with ranibizumab but resistant to

aflibercept were identified in a previously conducted retrospective study. Identified

patients will have their blood drawn for genome wide sequencing. The sequencing

data will be compiled and analyzed in an attempt to identify a common genetic basis

for patients susceptible to ranibizumab but resistant to aflibercept.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Ranibizumab

Intravitreal injection of Ranibizumab

DRUG

Aflibercept

Intravitreal injection of Aflibercept

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Associated Retinal Consultants, Michigan

    lead OTHER

Principal Investigators

  • Jeremy D Wolfe, MD, MS · Associated Retinal Consultants

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-22
Primary Completion
2015-07-01
Completion
2015-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02291887 on ClinicalTrials.gov